You are here: Home » Reuters » News
Business Standard

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

Reuters  |  FRANKFURT 

FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.The results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of cancer immunotherapies.Merck shares turned negative following the news, trading 1.1 percent lower. (Reporting by Ludwig Burger; Editing by Edward Taylor)(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Thu, February 15 2018. 20:00 IST